Future oncology (London, England) · 2018
A comparative evaluation of gemtuzumab ozogamicin + daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia.
СтатьяNetwork Meta-AnalysisНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ashaye Ajibade O, Khankhel Zarmina, Xu Yingxin, Fahrbach Kyle, Mokgokong Ruth, Orme Michelle E, Lang Kathryn, Cappelleri Joseph C, Mamolo Carla
Аннотация
AIM: To evaluate the comparative efficacy and safety of gemtuzumab ozogamicin + daunorubicin-cytarabine (GO + DA) versus common induction therapies for newly diagnosed acute myeloid leukemia. Materials & methods: A network meta-analysis following a systematic literature review.
RESULTS: In base-case analyses, GO + DA was associated with significantly greater overall survival and relapse-free survival versus most comparators, and similar rates of complete remission versus all evaluated comparators. Similar findings were seen in the subgroup analyses. Grade 3+ bleeding and hepatic events were higher with GO + DA versus some comparators, consistent with GO's profile. No differences were found for other evaluated outcomes.
CONCLUSION: GO + DA provides significant overall survival and relapse-free survival benefit versus evaluated induction regimens for newly diagnosed acute myeloid leukemia.
RESULTS: In base-case analyses, GO + DA was associated with significantly greater overall survival and relapse-free survival versus most comparators, and similar rates of complete remission versus all evaluated comparators. Similar findings were seen in the subgroup analyses. Grade 3+ bleeding and hepatic events were higher with GO + DA versus some comparators, consistent with GO's profile. No differences were found for other evaluated outcomes.
CONCLUSION: GO + DA provides significant overall survival and relapse-free survival benefit versus evaluated induction regimens for newly diagnosed acute myeloid leukemia.
Предметные рубрики MeSH
AdultAgedAminoglycosidesAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsClinical Trials as TopicCytarabineDaunorubicinFemaleGemtuzumabHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMulticenter Studies as TopicOdds RatioPublication BiasRandomized Controlled Trials as TopicRecurrenceRemission InductionSurvival RateTreatment Outcome